A Phase II study in adult patients with newly-diagnosed chronic myeloid leukaemia of initial intensified Glivec® therapy, and sequential combination therapy for non-responders, in order to assess response and survival (CML06)

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML

doi : http://doi.org/10.1182/blood-2005-03-1103

Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL

doi : http://doi.org/10.1038/sj.leu.2404139

Measurement of In Vivo BCR-ABL Kinase Inhibition to Monitor Imatinib-Induced Target Blockade and Predict Response in Chronic Myeloid Leukemia

doi : http://doi.org/10.1200/JCO.2006.09.9499

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

doi : http://doi.org/10.1182/blood-2007-06-093617

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

doi : http://doi.org/10.1182/blood-2008-06-161737

Classification of Patients With Chronic Myeloid Leukemia on Basis of BCR-ABL Transcript Level at 3 Months Fails to Identify Patients With Low Organic Cation Transporter-1 Activity Destined to Have Poor Imatinib Response

doi : http://doi.org/10.1200/JCO.2011.41.1090

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

doi : http://doi.org/10.1182/blood-2014-03-566323

BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management

doi : http://doi.org/10.1182/blood-2011-11-393041

Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients

doi : http://doi.org/10.1038/leu.2013.116

Australasian Leukaemia And Lymphoma Group (ALLG)

ROR : https://ror.org/05t72y326

Australasian Leukaemia and Lymphoma Group (ALLG)

ROR : https://ror.org/05t72y326